Array Biopharma, Inc. (ARRY) Posts Q4 Loss of 9c/Share, Narrower than Views
Tweet
Share
E-mailGet Alerts ARRY Hot Sheet
Price: $7.18 -0.83%
Revenue Growth %: -12.3%
Financial Fact:
Loss from operations: -24M
Today's EPS Names:
DTGI, CRMT, STZ, More
Revenue Growth %: -12.3%
Financial Fact:
Loss from operations: -24M
Today's EPS Names:
DTGI, CRMT, STZ, More
Join SI Premium – FREE
Array Biopharma, Inc. (NASDAQ: ARRY) reported Q4 EPS of ($0.09), $0.04 better than the analyst estimate of ($0.13). Revenue for the quarter came in at $20.7 million versus the consensus estimate of $21.45 million.
For earnings history and earnings-related data on Array Biopharma, Inc. (ARRY) click here.
For earnings history and earnings-related data on Array Biopharma, Inc. (ARRY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- SanDisk stock target lifted at Bernstein to $3000 on new memory LTAs
- Chip stocks hit record 19.7% of S&P 500, quadrupling since 2020
- Craig-Hallum Starts Aviat Networks (AVNW) at Buy
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
